Capreomycin

What is Capreomycin?

Capreomycin is an antimycobacterial antibiotic, primarily used in the treatment of various forms of tuberculosis (TB). Classified as a cyclic polypeptide, it is a crucial second-line agent, particularly effective against strains of TB that have developed resistance to first-line medications. It is administered as an injectable medication, either intramuscularly or intravenously, and is not available in oral form. Its role became increasingly significant with the rise of multi-drug resistant tuberculosis (MDR-TB), where conventional treatments are no longer effective. Discovered in the early 1960s, Capreomycin has since been an essential component of complex treatment regimens designed to combat the most challenging forms of this global infectious disease.

How Does it Work?

The mechanism of action of Capreomycin involves the inhibition of protein synthesis in mycobacteria, the bacteria responsible for tuberculosis. It achieves this by binding to the 30S ribosomal subunit and, to a lesser extent, the 50S ribosomal subunit of the bacterial ribosome. This interference disrupts the translation process, preventing the bacteria from producing essential proteins required for their growth and survival. While its exact binding site on the ribosome is distinct from that of aminoglycosides, it shares some structural similarities and a similar mode of action. Depending on the concentration achieved at the site of infection, Capreomycin can exhibit either bacteriostatic (inhibiting growth) or bactericidal (killing bacteria) activity against Mycobacterium tuberculosis. This targeted action against bacterial protein machinery makes it a potent weapon against persistent and resistant TB strains.

Medical Uses

The primary medical use of Capreomycin is in the treatment of tuberculosis, specifically for cases that are resistant to standard first-line antituberculosis drugs. It is a critical component of regimens for multi-drug resistant tuberculosis (MDR-TB), which is defined as TB resistant to at least isoniazid and rifampicin. Furthermore, it is also used in the treatment of extensively drug-resistant tuberculosis (XDR-TB), a more severe form of resistance. Capreomycin is never used as a monotherapy for TB; it is always administered as part of a multi-drug regimen to prevent the development of further resistance and to enhance its therapeutic efficacy. Its use is reserved for situations where susceptibility testing confirms its potential benefit or when other less toxic agents are not viable options.

Dosage

The typical dosage of Capreomycin for adults is 15 mg/kg of body weight, administered once daily via deep intramuscular injection or intravenous infusion. This dosing is usually given 5 to 7 days a week for the initial intensive phase of treatment, which can last for several months. Following this, the frequency may be reduced to 2 or 3 times per week during the continuation phase. The total duration of treatment for MDR-TB regimens involving Capreomycin is often prolonged, typically ranging from 12 to 24 months, depending on the patient's response and the specific resistance profile of the infection. Dosage adjustments are crucial for patients with renal impairment to prevent accumulation and reduce the risk of toxicity. Regular monitoring of kidney function and hearing is essential throughout the treatment period to ensure patient safety and optimize therapeutic outcomes.

Side Effects

Like many potent antibiotics, Capreomycin can cause several side effects of Capreomycin, some of which can be serious. The most significant adverse effects include nephrotoxicity (kidney damage) and ototoxicity (damage to the inner ear). Nephrotoxicity can manifest as elevated blood urea nitrogen (BUN) and creatinine levels, and in severe cases, acute kidney injury. Ototoxicity can lead to hearing loss (auditory damage), tinnitus (ringing in the ears), and vestibular dysfunction (balance problems). Other common side effects include pain, sterile abscess, or induration at the injection site. Electrolyte disturbances, such as hypokalemia (low potassium), hypomagnesemia (low magnesium), and hypocalcemia (low calcium), can also occur. Allergic reactions, including rash, fever, and urticaria, are possible. Due to the potential for severe adverse effects, patients receiving Capreomycin require close monitoring of renal function, audiometric testing, and electrolyte levels throughout the course of treatment.

Drug Interactions

Capreomycin has several important drug interactions that healthcare providers must consider to prevent increased toxicity. Concomitant use with other nephrotoxic drugs, such as aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, polymyxins, vancomycin, and cisplatin, significantly increases the risk of kidney damage. Similarly, co-administration with other ototoxic drugs, including aminoglycosides and loop diuretics (e.g., furosemide), can potentiate the risk of hearing loss and vestibular dysfunction. Capreomycin also possesses neuromuscular blocking properties, which can be additive when administered with other neuromuscular blocking agents, potentially leading to respiratory depression. Caution is advised when prescribing Capreomycin alongside drugs that affect electrolyte balance, as it can exacerbate electrolyte abnormalities. Always inform your doctor about all medications, supplements, and herbal products you are taking to ensure a safe and effective treatment plan.

FAQ

Is Capreomycin a first-line treatment for TB?

No, Capreomycin is not a first-line treatment. It is a second-line antituberculosis drug, reserved for cases of multi-drug resistant tuberculosis (MDR-TB) or extensively drug-resistant TB (XDR-TB) when first-line drugs are ineffective.

How is Capreomycin administered?

Capreomycin is an injectable medication. It is administered either as a deep intramuscular injection or as an intravenous infusion, typically on a daily or intermittent basis.

What should I do if I miss a dose of Capreomycin?

If you miss a dose of Capreomycin, contact your healthcare provider or pharmacist immediately for guidance. Do not double your dose to make up for a missed one, as this can increase the risk of side effects.

Can Capreomycin cause hearing loss?

Yes, ototoxicity is a known and serious side effect of Capreomycin. It can lead to permanent hearing loss, tinnitus, and balance problems. Regular audiometric monitoring is performed during treatment.

How long do I need to take Capreomycin?

Treatment with Capreomycin, as part of an MDR-TB regimen, is typically long-term, lasting from 12 to 24 months, depending on the severity of the resistance and the patient's response to therapy.

Products containing Capreomycin are available through trusted online pharmacies. You can browse Capreomycin-based medications at ShipperVIP or Medicenter.

Summary

Capreomycin stands as a vital antimycobacterial antibiotic in the global fight against tuberculosis, particularly against the challenging forms of multi-drug resistant tuberculosis (MDR-TB). As an injectable medication, it works by inhibiting bacterial protein synthesis, thereby stopping the growth and spread of Mycobacterium tuberculosis. While highly effective in severe cases, its use necessitates careful monitoring due to potential side effects of Capreomycin, notably nephrotoxicity and ototoxicity. Despite these considerations, Capreomycin remains an indispensable component of complex multi-drug regimens, offering a lifeline to patients facing drug-resistant TB and underscoring its critical role in public health.